| NCT03481634 | Novartis Pharmaceuticals | Diabetic Macular Edema | 2018-07-23 | PHASE3 |
| NCT02279537 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2014-01-02 | |
| NCT02681783 | Sunnybrook Health Sciences Centre | Central Serous Chorioretinopathy|Age Related Macular Degeneration|Idiopathic Poplypoidal Choroidal Vasculopathy | 2018-12-01 | PHASE4 |
| NCT03866746 | Al Hadi Hospital | Diabetic Macular Edema | 2017-05-08 | PHASE4 |
| NCT05850520 | Bayer|Regeneron Pharmaceuticals | Macular Edema Secondary to Retinal Vein Occlusion | 2023-05-15 | PHASE3 |
| NCT03468296 | Tennessee Retina|Regeneron Pharmaceuticals | Neovascular Age-related Macular Degeneration | 2018-04 | PHASE4 |
| NCT03370380 | University Hospital Muenster | Pigment Epithelial Detachment | 2015-04-17 | |
| NCT04049266 | Kodiak Sciences Inc | Wet Macular Degeneration | 2019-10-08 | PHASE2|PHASE3 |
| NCT02303184 | Clearside Biomedical, Inc. | Macular Edema|Retinal Vein Occlusion | 2015-01 | PHASE2 |
| NCT02432547 | University of Sydney|Center for Eye Research Australia | Diabetic Retinopathy | 2017-06-15 | PHASE4 |
| NCT03810313 | Novartis Pharmaceuticals | Central Retinal Vein Occlusion | 2019-07-03 | PHASE3 |
| NCT02689518 | University of California, San Diego|Regeneron Pharmaceuticals | Macular Degeneration|Wet Macular Degeneration | 2014-04 | PHASE4 |
| NCT06223958 | Ocular Therapeutix, Inc.|Fortrea|Duke University | Neovascular Age-Related Macular Degeneration | 2024-01-29 | PHASE3 |
| NCT03530267 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|STABIL - Statistische und Biometrische L?sungen|Trium Analysis Online GmbH|Sanofi | Colorectal Cancer | 2018-09-28 | PHASE2 |
| NCT03622593 | Hoffmann-La Roche | Diabetic Macular Edema | 2018-10-09 | PHASE3 |
| NCT01926977 | Arshad Khanani|Genentech, Inc. | Neovascular Age-Related Macular Degeneration | 2013-09 | PHASE1|PHASE2 |
| NCT04058067 | Novartis Pharmaceuticals | Diabetic Macular Edema | 2019-08-23 | PHASE3 |
| NCT04964089 | Kodiak Sciences Inc | Wet Age-related Macular Degeneration | 2021-06-23 | PHASE3 |
| NCT05941715 | Medical University of Graz | Neovascular Age-related Macular Degeneration | 2023-07-04 | PHASE4 |
| NCT01012973 | Bayer|Regeneron Pharmaceuticals | Retinal Vein Occlusion | 2009-10 | PHASE3 |
| NCT07434713 | Insel Gruppe AG, University Hospital Bern | Age-Related Macular Degeneration (AMD) | 2025-07-14 | |
| NCT03038048 | Wills Eye|Mid Atlantic Retina | Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion | 2017-01-27 | NA |
| NCT01646554 | European Organisation for Research and Treatment of Cancer - EORTC|Sanofi | Colorectal Cancer Metastatic|Liver Metastases|KRAS Mutated Colorectal Cancer | 2012-12 | PHASE2|PHASE3 |
| NCT02441816 | Moorfields Eye Hospital NHS Foundation Trust | Age Related Macular Degeneration | 2014-11 | PHASE4 |
| NCT06491914 | Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema | 2024-07-24 | PHASE3 |
| NCT04087746 | Minia University | Diabetic Macular Edema | 2017-01 | PHASE4 |
| NCT01969708 | The Emmes Company, LLC|National Eye Institute (NEI)|Milton S. Hershey Medical Center|University of Wisconsin, Madison | Central Retinal Vein Occlusion | 2014-09 | PHASE3 |
| NCT02586727 | Larkin Community Hospital | Adverse Effect of Radiation Therapy | 2015-10 | PHASE2 |
| NCT04137120 | Bayer | Retinal Disease | 2021-02-19 | |
| NCT06683950 | Kim´s Eye Hospital | Age-related Macular Degeneration (ARMD) | 2024-10-21 | PHASE4 |
| NCT02949024 | Clearside Biomedical, Inc. | Diabetic Macular Edema | 2016-11-10 | PHASE1|PHASE2 |
| NCT01579760 | Washington University School of Medicine|Regeneron Pharmaceuticals | Radiation Retinopathy|Macular Edema | 2012-11 | PHASE1 |
| NCT02624726 | Hellenic Oncology Research Group | Metastatic Colorectal Cancer | 2016-01 | PHASE2 |
| NCT07489586 | Qilu Pharmaceutical Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 2026-03 | PHASE3 |
| NCT07489131 | Alvotech Swiss AG | Diabetic Macular Edema | 2026-04-22 | PHASE3 |
| NCT05178745 | Sanofi | Metastatic Colorectal Cancer|Colorectal Neoplasms | 2016-09-07 | |
| NCT02129257 | Hellenic Cooperative Oncology Group|Sanofi | Metastatic Colorectal Cancer | 2014-05-26 | PHASE2 |
| NCT03651011 | Odense University Hospital|Danske Regioner|Synoptik-Fonden|Toyota-Fonden|AP Moeller Foundation|Yamagata University|Queen´s University, Belfast|Zealand University Hospital|Region Sj?llands og Region Syddanmarks forskningspulje | Branch Retinal Vein Occlusion|Macular Edema | 2018-08-10 | NA |
| NCT01857544 | Tennessee Retina|Regeneron Pharmaceuticals | Retinal Vein Occlusion | 2013-06 | PHASE4 |
| NCT03630952 | Chengdu Kanghong Biotech Co., Ltd. | Neovascular Age-related Macular Degeneration | 2018-12-21 | PHASE3 |
| NCT01971190 | Asan Medical Center | Central Serous Chorioretinopathy | 2013-10 | PHASE2 |
| NCT01958918 | Novartis Pharmaceuticals | Neovascular Age-related Macular Degeneration | 2013-10-23 | PHASE4 |
| NCT02615496 | Bayer|RTI Health Solutions | Macular Degeneration | 2015-12-07 | |
| NCT01805297 | University of Oklahoma | Vitreous Hemorrhage | 2013-03 | PHASE2 |
| NCT02581891 | Bayer|Regeneron Pharmaceuticals | Macular Degeneration | 2015-11-19 | PHASE4 |
| NCT05403749 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration | 2022-06-29 | PHASE2 |
| NCT01670721 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2012-08 | PHASE3 |
| NCT07440225 | EyeBiotech Ltd. | Macular Degeneration|Age-Related Macular Degeneration|Choroidal Neovascularization|Wet Macular Degeneration | 2026-03-27 | PHASE2|PHASE3 |
| NCT01824225 | Nihon University | Age-related Macular Degeneration | 2013-03 | PHASE4 |
| NCT04698850 | Faculty Hospital Kralovske Vinohrady | Wet Macular Degeneration | 2021-01-04 | PHASE4 |
| NCT04580147 | M. Ali Khan, MD|Southeastern Retina Associates|Eye Associates of New Mexico|University of California, Los Angeles | Retinal Detachment With Multiple Breaks, Unspecified Eye|Proliferative Vitreoretinopathy | 2020-10-15 | PHASE2 |
| NCT04005352 | Novartis Pharmaceuticals | Age-related Macular Degeneration | 2019-09-25 | PHASE3 |
| NCT03453281 | Indonesia University|Bayer | Diabetic Macular Edema|Diabetic Retinopathy|Clinically Significant Macular Edema | 2017-10-10 | PHASE4 |
| NCT07526857 | Federico II University | Diabetic Retinopathy, DR | 2025-01-01 | |
| NCT02878681 | Novartis Pharmaceuticals | Visual Impairment Due to Diabetic Macular Edema | 2016-09 | PHASE4 |
| NCT04519619 | Bayer | Neovascular Glaucoma | 2020-11-27 | |
| NCT02559180 | Rishi Singh|Regeneron Pharmaceuticals | Diabetic Retinopathy|Macular Edema | 2015-10 | PHASE4 |
| NCT02000102 | Stanford University | Diabetic Macular Edema | 2013-09 | |
| NCT07118670 | Edward Wood, MD|Greater Houston Retina Research | Proliferative Diabetic Retinopathy (PDR) | 2025-12-08 | PHASE4 |
| NCT02788877 | Pusan National University Hospital|Novartis | Macular Edema, Diabetic | 2016-04-10 | PHASE4 |
| NCT03709745 | St. Erik Eye Hospital | Branch Retinal Vein Occlusion with Macular Edema | 2018-10-18 | PHASE4 |
| NCT06839339 | Beijing Anlong Biopharmaceutical Co., Ltd. | Wet Age-related Macular Degeneration (wAMD) | 2025-02-18 | PHASE2 |
| NCT03710564 | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 2018-10-30 | PHASE3 |
| NCT03780361 | Hyewon Chung|Bayer | Diabetic Macular Edema | 2019-05-17 | PHASE4 |
| NCT04820452 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration | 2021-04-28 | PHASE2 |
| NCT02418754 | Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 2015-05-05 | PHASE2 |
| NCT02540369 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2015-12-14 | |
| NCT02811692 | Bayer|Regeneron Pharmaceuticals | Eye Diseases | 2016-09-30 | |
| NCT05381948 | EyePoint Pharmaceuticals, Inc. | Wet Age-related Macular Degeneration | 2022-06-30 | PHASE2 |
| NCT03355638 | Università degli Studi di Brescia | Macular Edema | 2016-01 | PHASE4 |
| NCT04113538 | Michel Giunta|Bayer | Wet Age-related Macular Degeneration | 2019-07-24 | PHASE3 |
| NCT03594461 | Vitreous -Retina- Macula Consultants of New York | Neovascular Age-Related Macular Degeneration | 2018-09-11 | PHASE1|PHASE2 |
| NCT04684394 | Gemini Therapeutics, Inc. | Neovascular Age-related Macular Degeneration|Retinal Disease|Retinal Degeneration|Macular Degeneration | 2020-12-29 | PHASE2 |
| NCT04663750 | King´s College Hospital NHS Trust|King´s College London|Fight for Sight (Funder) | Eye Diseases|Macular Degeneration, Wet|Sub-Macular Hemorrhage | 2021-04-16 | PHASE3 |
| NCT03452527 | Iconic Therapeutics, Inc. | Choroidal Neovascularization|Wet Macular Degeneration | 2018-03-26 | PHASE2 |
| NCT04655482 | Kim´s Eye Hospital|Bayer | Retinal Angiomatous Proliferation | 2021-02-01 | PHASE4 |
| NCT04429503 | Regeneron Pharmaceuticals|Bayer | Diabetic Macular Edema|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus | 2020-06-29 | PHASE2|PHASE3 |
| NCT02309281 | Vista Klinik|Bayer | Neovascular Age-related Macular Degeneration | 2013-05 | PHASE4 |
| NCT04708145 | Greater Houston Retina Research|Regeneron Pharmaceuticals|Clinical Trials Resource Group, LLC | Diabetic Retinopathy | 2021-06-01 | PHASE4 |
| NCT04603937 | Kodiak Sciences Inc | Diabetic Macular Edema | 2020-09-30 | PHASE3 |
| NCT02218177 | University Health Network, Toronto | Age Related Macular Degeneration | 2014-08 | |
| NCT02085005 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2014-03 | PHASE2 |
| NCT01783886 | Bayer|Regeneron Pharmaceuticals | Macular Edema | 2013-02 | PHASE3 |
| NCT02321241 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2016-02-01 | |
| NCT05126966 | Hoffmann-La Roche | Neovascular Age-Related Macular Degeneration | 2023-12-29 | PHASE3 |
| NCT04079231 | Novartis Pharmaceuticals | Diabetic Macula Edema | 2021-02-01 | PHASE3 |
| NCT01526070 | Stanford University | Exudative Age-related Macular Degeneration | 2012-01 | |
| NCT05972473 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration | 2023-09-21 | PHASE3 |
| NCT05324774 | Mabwell (Shanghai) Bioscience Co., Ltd. | Diabetic Macular Edema | 2022-02-28 | PHASE3 |
| NCT02291887 | Associated Retinal Consultants, Michigan|Genentech, Inc. | Age-Related Macular Degeneration | 2014-12-22 | |
| NCT07449936 | EyePoint Pharmaceuticals, Inc. | Diabetic Macular Edema|DME|Diabetic Macular Edema (DME) | 2026-02-16 | PHASE3 |
| NCT06591598 | Bayer|Regeneron Pharmaceuticals | Diabetic Macular Edema|Neovascular Age-related Macular Degeneration | 2024-09-02 | PHASE4 |
| NCT00921661 | Sanofi|Regeneron Pharmaceuticals | Colorectal Neoplasms|Neoplasm Metastasis | 2009-06 | PHASE1 |
| NCT07482176 | Adverum Biotechnologies, Inc. | Neovascular Age-Related Macular Degeneration (nAMD)|Wet AMD | 2026-03-16 | PHASE3 |
| NCT00644124 | Sanofi|Regeneron Pharmaceuticals | Lymphoma, Non-Hodgkin | 2008-03 | PHASE1 |
| NCT02396316 | Bayer|Regeneron Pharmaceuticals | Glaucoma, Neovascular | 2015-04-02 | PHASE3 |
| NCT01961414 | Palmetto Retina Center, LLC | Exudative Age-related Macular Degeneration | 2013-10 | PHASE4 |
| NCT03823287 | Hoffmann-La Roche | Wet Macular Degeneration | 2019-02-19 | PHASE3 |
| NCT05155293 | Alvotech Swiss AG | Neovascular (Wet) AMD | 2022-06-28 | PHASE3 |
| NCT02818998 | Bayer | Macular Edema | 2016-11-16 | PHASE3 |
| NCT05407636 | AbbVie|REGENXBIO Inc. | AMD|nAMD|Wet Age-related Macular Degeneration|wAMD|WetAMD|CNV | 2022-01-13 | PHASE3 |
| NCT05345236 | Qilu Pharmaceutical Co., Ltd. | Wet Age-related Macular Degeneration | 2019-08-19 | PHASE3 |
| NCT02258009 | Novartis Pharmaceuticals | Visual Impairment Due to Diabetic Macular Edema | 2015-10 | PHASE4 |
| NCT07496567 | EyeBiotech Ltd. | Macular Degeneration|Age-Related Macular Degeneration|Choroidal Neovascularization|Wet Macular Degeneration | 2026-04-15 | PHASE2|PHASE3 |
| NCT03939767 | Bayer | Wet Age-related Macular Degeneration | 2019-05-12 | |
| NCT02797704 | Rabin Medical Center | Corneal Neovascularization | 2017-03-02 | PHASE1|PHASE2 |
| NCT02597855 | Yeungnam University College of Medicine | Polypoidal Choroidal Vasculopathy | 2015-09 | |
| NCT00876044 | Sanofi|Regeneron Pharmaceuticals | Cancer | 2009-04 | PHASE1 |
| NCT00789477 | Regeneron Pharmaceuticals|Bayer | Diabetic Macular Edema | 2008-12 | PHASE2 |
| NCT00327444 | Sanofi|Regeneron Pharmaceuticals | Ovarian Neoplasms|Ascites | 2006-07 | PHASE2|PHASE3 |
| NCT05710471 | The University of Hong Kong | Age-Related Macular Degeneration | 2022-07-25 | PHASE4 |
| NCT02641457 | Instituto de Olhos de Goiania | Glaucoma|Rubeosis Iridis | 2014-03 | PHASE3 |
| NCT04707027 | Chiang Mai University | Polypoidal Choroidal Vasculopathy | 2020-11-01 | NA |
| NCT01773954 | MidAtlantic Retina|Regeneron Pharmaceuticals | Age-Related Macular Degeneration|Macular Degeneration | 2013-02 | NA |
| NCT02924311 | Bayer|Regeneron Pharmaceuticals | Diabetic Retinopathy | 2016-09-21 | |
| NCT02321267 | Kagawa University | Macular Disease | 2014-12 | PHASE4 |
| NCT05731089 | Al Hadi Hospital | Diabetic Macular Edema | 2019-09-01 | NA |
| NCT02305238 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2014-12-19 | PHASE4 |
| NCT00794417 | Regeneron Pharmaceuticals|Sanofi | Advanced Carcinoma|Non-small Cell Lung Cancer | 2008-11-30 | PHASE1|PHASE2 |
| NCT01796964 | Alcon Research | Exudative Age-Related Macular Degeneration | 2013-03 | PHASE2 |
| NCT02157077 | Centre Hospitalier Intercommunal Creteil|Bayer | Macular Degeneration|Wet Macular Degeneration|Retinal Degeneration|Retinal Diseases|Eye Diseases | 2013-12 | PHASE3 |
| NCT02425501 | Bayer | Macular Edema | 2015-01-20 | |
| NCT05063734 | Oxurion | Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema | 2021-08-27 | PHASE2 |
| NCT00574275 | Sanofi|Regeneron Pharmaceuticals | Pancreatic Neoplasm | 2007-12 | PHASE3 |
| NCT00407654 | National Cancer Institute (NCI) | Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer | 2006-10 | PHASE2 |
| NCT06929143 | Bayer | Neovascular Age-related Macular Degeneration (nAMD)|Diabetic Macular Edema (DME) | 2025-04-14 | |
| NCT02540954 | Bayer | Macular Degeneration | 2015-09-29 | PHASE3 |
| NCT03920878 | Emory University | Diabetic Macular Edema|Cataract | 2020-05 | PHASE2 |
| NCT01918878 | Hadassah Medical Organization|Bayer | Neovascular Age-related Macular Degeneration | 2013-10 | PHASE4 |
| NCT03249740 | Graybug Vision | Neovascular Age-Related Macular Degeneration | 2017-08-29 | PHASE1 |
| NCT00545246 | Sanofi|Regeneron Pharmaceuticals | Neoplasms | 2007-10 | PHASE1 |
| NCT03056079 | Unity Health Toronto | Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion|Macular Edema | 2017-02-28 | PHASE4 |
| NCT03832179 | Bay Area Retina Associates|Allergan | Diabetic Macular Edema|Cataract | 2018-11-15 | PHASE4 |
| NCT03405376 | Yeungnam University College of Medicine | Branch Retinal Vein Occlusion With Macular Edema | 2018-01-25 | PHASE4 |
| NCT05704725 | Amgen | Chorioretinal Vascular Disease | 2023-01-23 | PHASE3 |
| NCT02541084 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2015-08-18 | |
| NCT04469595 | Alimera Sciences | Diabetic Macular Edema | 2020-08-31 | PHASE4 |
| NCT04450329 | Samsung Bioepis Co., Ltd. | Neovascular Age-related Macular Degeneration | 2020-06-23 | PHASE3 |
| NCT03278262 | Bayer|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2017-09-01 | |
| NCT01868360 | Balamurali Ambati|Regeneron Pharmaceuticals | Corneal Neovascularization | 2013-06 | PHASE1 |
| NCT03714308 | Bayer | Macular Degeneration | 2019-01-28 | |
| NCT02120950 | Bayer|Regeneron Pharmaceuticals | Neovascular Macular Degeneration | 2014-05-29 | PHASE4 |
| NCT02297204 | Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2014-11 | PHASE4 |
| NCT05891548 | Clearside Biomedical, Inc. | Neovascular Age-related Macular Degeneration | 2023-05-31 | PHASE2 |
| NCT02403128 | Kamal Kishore, MD | Macular Edema|Retinal Artery Macroaneurysm | 2015-05-14 | PHASE1 |
| NCT04411693 | The Cleveland Clinic|Allergan | Diabetic Macular Edema | 2020-04-10 | PHASE4 |
| NCT02363621 | Arshad Khanani|Genentech, Inc. | Diabetic Macular Edema | 2015-01 | PHASE2 |
| NCT03022292 | University of California, Los Angeles|Regeneron Pharmaceuticals | Wet Macular Degeneration | 2017-03-30 | PHASE4 |
| NCT05990829 | Tianjin Medical University Eye Hospital|AbbVie | Diabetic Macular Edema|Pars Plana Vitrectomy|Dexamethasone Intravitreal Implant|Intraoperative Optical Coherence Tomography | 2023-10-01 | PHASE4 |
| NCT02387957 | Ophthotech Corporation | Age-Related Macular Degeneration | 2016-04-26 | PHASE2 |
| NCT07301775 | Ahmad Zeeshan Jamil|Sahiwal medical college sahiwal | Diabetic Retinopathy (DR)|Diabetic Macular Edema (DME)|Cataract|Phacoemulfisication&addition;IOL Implantation|Intravitreal Injection | 2026-01-01 | PHASE4 |
| NCT02401945 | Santen Inc. | Age-Related Macular Degeneration | 2015-04 | PHASE2 |
| NCT02118831 | California Retina Consultants | Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion | 2012-03 | PHASE1|PHASE2 |
| NCT03126786 | Clearside Biomedical, Inc. | Diabetic Macular Edema | 2017-07-11 | PHASE2 |
| NCT04522167 | Bioeq GmbH | Neovascular Age-related Macular Degeneration | 2020-07-21 | PHASE3 |
| NCT05683912 | University of Athens | Diabetic Macular Edema | 2019-09-01 | |
| NCT03917472 | Novartis Pharmaceuticals | Diabetic Macular Edema | 2019-07-17 | PHASE3 |
| NCT04101877 | Vastra Gotaland Region | Neovascular Age-related Macular Degeneration | 2020-09-03 | PHASE2 |
| NCT01746875 | Norwegian University of Science and Technology | Macular Degeneration|Retinal Detachment | 2014-02 | NA |
| NCT02331927 | University of Ulm|Hubertus-Wald-Cancer Center Hamburg, Germany|Sanofi|Assign Data Management and Biostatistics GmbH | Metastatic Colorectal Cancer | 2015-03 | PHASE2 |
| NCT01940887 | Ophthotech Corporation | Age-Related Macular Degeneration | 2014-05 | PHASE3 |
| NCT04200248 | Ribomic USA Inc | Exudative Age-related Macular Degeneration | 2019-12-02 | PHASE2 |
| NCT04126317 | Regeneron Pharmaceuticals|Bayer | Neovascular (Wet) Age-Related Macular Degeneration | 2019-11-04 | PHASE2 |
| NCT03186326 | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer|MSI | 2018-04-24 | PHASE2 |
| NCT02503540 | Justis Ehlers|Regeneron Pharmaceuticals | Retinal Vein Occlusion|Diabetic Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion | 2015-08-18 | PHASE4 |
| NCT03264274 | Barts & The London NHS Trust|Sanofi | Colorectal Cancer | 2017-02-06 | PHASE2 |
| NCT04702048 | University of Rochester | Retinopathy, Diabetic | 2021-02-01 | PHASE4 |
| NCT00320788 | Regeneron Pharmaceuticals|Bayer | Macular Degeneration | 2006-04 | PHASE2 |
| NCT06398080 | Regeneron Pharmaceuticals | Neovascular Age-related Macular Degeneration (nAMD)|Wet Age-related Macular Degeneration (AMD)|Diabetic Macular Edema (DME)|Visual Impairment | 2024-12-12 | |
| NCT04418427 | Adverum Biotechnologies, Inc. | Diabetic Macular Edema|Diabetic Retinopathy | 2020-05-28 | PHASE2 |
| NCT05961007 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration|Diabetic Macular Edema | 2021-11-18 | PHASE1|PHASE2 |
| NCT00637377 | Bayer|Regeneron Pharmaceuticals | Macular Degeneration | 2008-04 | PHASE3 |
| NCT06769412 | Regeneron Pharmaceuticals | Retinal Vasculitis | 2025-07-01 | |
| NCT00851084 | Sanofi | Colorectal Neoplasms|Neoplasm Metastasis | 2009-02 | PHASE2 |
| NCT03059277 | Southeast Clinical Research Associates, LLC|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2018-06-01 | PHASE4 |
| NCT02645747 | Bayer|Regeneron Pharmaceuticals | Retinal Vein Occlusion | 2016-01-21 | |
| NCT04270747 | Amgen|Parexel | Neovascular (Wet) Age-related Macular Degeneration (AMD) | 2020-06-22 | PHASE3 |
| NCT03172299 | Centre Hospitalier Universitaire de Nice | Ocular Melanoma | 2017-06-08 | PHASE3 |
| NCT04480463 | Sam Chun Dang Pharm. Co. Ltd. | Wet Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration | 2020-08-13 | PHASE3 |
| NCT03531294 | Greater Houston Retina Research|Regeneron Pharmaceuticals|The Cleveland Clinic | Diabetic Retinopathy | 2018-05-23 | PHASE2 |
| NCT05930561 | 4D Molecular Therapeutics | Diabetic Macular Edema|Diabetic Retinopathy | 2023-08-09 | PHASE2 |
| NCT02556229 | Hospices Civils de Lyon | Inflammatory Choroidal Neovascularization | 2016-06 | PHASE2 |
| NCT02151695 | Poitiers University Hospital | Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy | 2015-05 | PHASE2 |
| NCT07338097 | CMH Multan Institute of Medical Sciences | Diabetic Macular Edema (DME) | 2025-09-07 | NA |
| NCT01756261 | Bayer|Regeneron Pharmaceuticals | Macular Degeneration | 2012-12-26 | |
| NCT03321513 | Jaeb Center for Health Research | Diabetic Macular Edema | 2017-12-07 | PHASE3 |
| NCT04370379 | Innovent Biologics (Suzhou) Co. Ltd. | Neovascular Age-related Macular Degeneration | 2020-05-28 | PHASE1 |
| NCT01965041 | Manhattan Eye, Ear & Throat Hospital|Northwell Health | Pattern Dystrophy of Macula | 2013-10 | NA |
| NCT04740905 | Hoffmann-La Roche|Chugai Pharmaceutical | Macular Edema|Branch Retinal Vein Occlusion | 2021-03-02 | PHASE3 |
| NCT01950741 | Pusan National University Hospital|Bayer | Exudative Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy | 2013-09 | PHASE4 |
| NCT05727397 | RemeGen Co., Ltd. | Wet Age-related Macular Degeneration | 2023-03-14 | PHASE3 |
| NCT03386474 | Novartis Pharmaceuticals | Neovascular Age-related Macular Degeneration | 2018-01-15 | PHASE3 |
| NCT02392364 | California Retina Consultants|Regeneron Pharmaceuticals | Cystoid Macular Edema|Diabetic Macular Edema | 2015-04-15 | PHASE4 |
| NCT00479076 | Sanofi|Regeneron Pharmaceuticals | Neoplasms | 2007-03 | PHASE1 |
| NCT01495208 | Vitreous -Retina- Macula Consultants of New York|Regeneron Pharmaceuticals | Fibrovascular Pigment Epithelial Detachment | 2011-12 | PHASE4 |
| NCT05197270 | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 2021-12-09 | PHASE1|PHASE2 |
| NCT06315556 | Bayer | Retinopathy of Prematurity|Preterm Infants | 2024-03-05 | |
| NCT02646670 | Instituto de Olhos de Goiania | Retinal Diseases | 2015-07 | PHASE4 |
| NCT06878573 | Augenabteilung Allgemeines Krankenhaus Linz | Age Related Macular Degeneration|Diabetic Macular Edema | 2023-11-22 | |
| NCT04970251 | Siriraj Hospital | Intraocular Pressure|Neovascular Glaucoma|Vascular Endothelial Growth Factor Overexpression|Glaucoma Secondary to Eye Inflammation | 2018-11-01 | NA |
| NCT05251636 | Salutaris Medical Devices, Inc. | Age-Related Macular Degeneration|Polypoid Choroidal Vasculopathy | 2025-03 | PHASE3 |
| NCT04014556 | University of Alexandria | Diabetic Macular Edema | 2016-04-01 | NA |
| NCT03622580 | Hoffmann-La Roche | Diabetic Macular Edema | 2018-09-05 | PHASE3 |
| NCT02858076 | Jaeb Center for Health Research|National Institutes of Health (NIH)|Regeneron Pharmaceuticals|National Eye Institute (NEI) | Proliferative Diabetic Retinopathy|Vitreous Hemorrhage | 2016-11 | PHASE2|PHASE3 |
| NCT03324542 | Changhua Christian Hospital | AMD | 2017-04-03 | |
| NCT01914380 | Bayer|Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 2013-07-29 | |
| NCT06683742 | EyePoint Pharmaceuticals, Inc. | Wet Age Related Macular Degeneration|wAMD | 2024-11-27 | PHASE3 |
| NCT06864988 | 4D Molecular Therapeutics | Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2025-03-03 | PHASE3 |
| NCT01669720 | Brown University|Rhode Island Hospital|The Miriam Hospital|Lifespan|University of California, San Diego|Montefiore Medical Center|University of Florida|Sanofi | Metastatic Colorectal Cancer | 2012-12 | PHASE2 |
| NCT02320474 | Poitiers University Hospital | Type 3 Choroidal Neovascularization | 2014-11-25 | PHASE4 |
| NCT02072408 | Samsung Medical Center|Seoul National University Bundang Hospital|Kim´s Eye Hospital|Bayer | Polypoidal Choroidal Vasculopathy Without Active Polyp | 2014-02 | PHASE4 |
| NCT06556368 | Kodiak Sciences Inc | Wet Age-related Macular Degeneration | 2024-08-23 | PHASE3 |
| NCT06196840 | Innostellar Biotherapeutics Co.,Ltd | Neovascular Age-Related Macular Degeneration | 2024-01-24 | PHASE2 |
| NCT05989126 | Regeneron Pharmaceuticals | Diabetic Macular Edema (DME)|Neovascular Age-Related Macular Degeneration (nAMD) | 2024-04-15 | PHASE3 |
| NCT00964795 | Regeneron Pharmaceuticals|Bayer | Neovascular Age-related Macular Degeneration | 2009-12 | PHASE3 |
| NCT02734407 | Retina-Vitreous Associates Medical Group | Clinically Significant Diabetic Macular Edema | 2015-01 | PHASE4 |
| NCT00327171 | Sanofi|Regeneron Pharmaceuticals | Neoplasms|Cancer of the Ovary | 2006-05 | PHASE2 |
| NCT07064759 | 4D Molecular Therapeutics | Neovascular Age-Related Macular Degeneration (nAMD) | 2025-07-22 | PHASE3 |
| NCT07365371 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Bayer | Polypoidal Choroidal Vasculopathy (PCV)|Neovascular Age Related Macular Degeneration (AMD) | 2026-01-01 | PHASE4 |
| NCT00561470 | Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc | Colorectal Neoplasms|Neoplasm Metastasis | 2007-11 | PHASE3 |
| NCT07205887 | EyeBiotech Ltd. | Neovascular Age-Related Macular Degeneration (NVAMD)|Branch Retinal Vein Occlusion (BRVO) | 2025-09-12 | PHASE2 |
| NCT02924987 | Maisonneuve-Rosemont Hospital|Bayer | Diabetic Macular Edema | 2016-11 | PHASE4 |
| NCT02462889 | Jeffrey S Heier|Regeneron Pharmaceuticals | Age-Related Macular Degeneration | 2015-06 | PHASE2 |
| NCT02860858 | Department of Medical Services Ministry of Public Health of Thailand | Symtomatic Macular Polypoidal Choroidal Vasculopathy | 2016-12-30 | PHASE4 |
| NCT03974425 | University of Alexandria | Diabetic Macular Edema | 2016-04-01 | NA |
| NCT02772497 | Marashi Eye Clinic | Diabetic Macular Edema | 2016-01 | PHASE2|PHASE3 |
| NCT04932980 | Berner Augenklinik|medignition AG | Wet Age-related Macular Degeneration | 2022-05-09 | NA |
| NCT03290794 | Bayer | Wet Age-related Macular Degeneration | 2019-02-14 | |
| NCT05275205 | Unity Biotechnology, Inc. | Neovascular Age-related Macular Degeneration | 2022-03-02 | PHASE2 |
| NCT01670162 | Tennessee Retina|Regeneron Pharmaceuticals | Age Related Macular Degeneration|Pigment Epithelial Detachment | 2012-08 | PHASE4 |
| NCT02630277 | Valley Retina Institute | Proliferative Diabetic Retinopathy | 2016-01 | PHASE2 |
| NCT03006081 | Asan Medical Center | Diabetic Retinopathy | 2016-04-14 | PHASE2 |
| NCT06879301 | Tanta University | Diabetic Macular Edema (DME)|Retinal Vein Occlusion (RVO)|Myopic Choroidal Neovascularisation | 2025-10-19 | EARLY_PHASE1 |
| NCT02181556 | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer | 2014-10 | PHASE2 |
| NCT01813773 | Ophthalmic Consultants of Long Island|Regeneron Pharmaceuticals | Proliferative Diabetic Retinopathy | 2013-03 | PHASE2|PHASE3 |
| NCT02863354 | Charles C Wykoff, PhD, MD|Regeneron Pharmaceuticals | Proliferative Diabetic Retinopathy | 2016-08 | PHASE2 |
| NCT04524910 | Bayer | Myopic Choroidal Neovascularization | 2021-06-16 | |
| NCT04567550 | AbbVie|REGENXBIO Inc. | Diabetic Retinopathy (DR)|Center-Involved Diabetic Macular Edema (CI-DME) | 2020-11-20 | PHASE2 |
| NCT01521559 | Regeneron Pharmaceuticals|Bayer | Branch Retinal Vein Occlusion | 2012-04 | PHASE3 |
| NCT05705258 | Bayer | Retinopathy of Prematurity|Newborns|Infants | 2023-03-27 | |
| NCT01871376 | Gregg T. Kokame, MD|Regeneron Pharmaceuticals | Polypoidal Choroidal Vasculopathy | 2013-05 | PHASE4 |
| NCT03639675 | Bayer|Regeneron Pharmaceuticals | Glaucoma, Neovascular | 2018-10-03 | PHASE3 |
| NCT03823300 | Hoffmann-La Roche | Wet Macular Degeneration | 2019-03-11 | PHASE3 |
| NCT01870427 | Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals | Macular Edema With Central Retinal Vein Occlusions | 2013-06 | PHASE4 |
| NCT01955629 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2013-12 | PHASE1|PHASE2 |
| NCT02092532 | Southeast Retina Center, Georgia|Regeneron Pharmaceuticals | Neovascular Polypoidal Choroidal Vasculopathy | 2014-03 | PHASE4 |
| NCT04662944 | Novartis Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 2021-02-23 | |
| NCT01652196 | John Hays|Sanofi | Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer | 2012-11-14 | PHASE2 |
| NCT01363440 | Regeneron Pharmaceuticals|Bayer | Diabetic Macular Edema | 2011-05 | PHASE3 |
| NCT04423718 | Bayer|Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 2020-08-11 | PHASE3 |
| NCT01627249 | Jaeb Center for Health Research|National Eye Institute (NEI)|Genentech, Inc.|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2012-08 | PHASE3 |
| NCT05222633 | Wenbin Wei | Neovascular Age-related Macular Edema|Diabetic Macular Edema|Choroidal Neovascular Membrane|Non-proliferative Diabetic Retinopathy|Retinal Vein Occlusion|Proliferative Diabetic Retinopathy | 2022-01-01 | |
| NCT02260687 | Bayer|Regeneron Pharmaceuticals | Choroidal Neovascularization | 2014-12-05 | |
| NCT02495181 | Association for Innovation and Biomedical Research on Light and Image|European Vision Institute Clinical Research Network | Polypoidal Choroidal Vasculopathy | 2015-11-23 | PHASE4 |
| NCT03161912 | Bayer|Regeneron Pharmaceuticals | Macular Edema | 2017-11-24 | |
| NCT05342857 | Shin Kong Wu Ho-Su Memorial Hospital | Neovascular Age-related Macular Degeneration | 2022-01-01 | |
| NCT02441907 | Unity Health Toronto | Diabetic Macular Edema | 2015-08 | PHASE4 |
| NCT02661711 | Moorfields Eye Hospital NHS Foundation Trust|Bayer | Macular Oedema|Retinitis Pigmentosa | 2016-03 | PHASE2 |
| NCT06099184 | EyePoint Pharmaceuticals, Inc. | Diabetic Macular Edema | 2024-01-15 | PHASE2 |
| NCT07096713 | Benha University | Anti-VEGF Therapy | 2024-01-01 | NA |
| NCT07557121 | AiViva BioPharma, Inc.|ClinDatrix, Inc. | Neovascular (Wet) Age-Related Macular Degeneration | 2026-07-01 | PHASE2 |
| NCT05511038 | Bayer | Diabetic Macular Edema | 2022-08-26 | PHASE4 |
| NCT03766425 | Medical University of Lublin | Eye Diseases|Optic Nerve Damage|Glaucoma Surgery | 2017-06-14 | EARLY_PHASE1 |
| NCT02130024 | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 2014-04-11 | PHASE4 |
| NCT06495918 | Ocular Therapeutix, Inc.|Fortrea|Duke University | Neovascular Age-related Macular Degeneration | 2024-11-27 | PHASE3 |
| NCT01896284 | Barcelona Macula Foundation|TFS Trial Form Support|Bayer | Wet Macular Degeneration | 2013-07 | PHASE4 |
| NCT04018833 | Bernardete Pessoa MD | Diabetic Macular Edema|Diabetic Retinopathy | 2012-01-01 | |
| NCT02340949 | Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L. | Rectal Cancer | 2015-01 | PHASE2 |
| NCT02800642 | Bayer | Central Retinal Vein Occlusion | 2016-06-10 | PHASE4 |
| NCT06132035 | Caregen Co. Ltd.|CBCC Global Research | Age-related Wet Macular Degeneration | 2023-12-22 | PHASE1 |
| NCT06330220 | Seoul National University Hospital | Age-Related Macular Degeneration | 2021-02-10 | PHASE4 |
| NCT06011798 | Unity Biotechnology, Inc. | Diabetic Macular Edema|Retinal Disease|Macular Edema|Diabetes Mellitus|Diabetic Retinopathy|Retinal Degeneration|Retinal Diseases|Eye Diseases|Edema | 2023-08-23 | PHASE2 |
| NCT01617148 | Rishi Singh|Regeneron Pharmaceuticals | Exudative Macular Degeneration | 2012-06 | PHASE4 |
| NCT04611152 | Kodiak Sciences Inc | Diabetic Macular Edema | 2020-09-30 | PHASE3 |
| NCT04757636 | Opthea Limited | Neovascular Age-related Macular Degeneration | 2021-03-12 | PHASE3 |
| NCT01722656 | Southern California Desert Retina Consultants, MC|Regeneron Pharmaceuticals | Submacular Vascularized Pigment Epithelial Detachments | 2012-11 | PHASE4 |
| NCT06817343 | Exegenesis Bio | Neovascular Age-Related Macular Degeneration (nAMD)|Neovascular (Wet) Age-related Macular Degeneration (AMD) | 2024-09-10 | PHASE1 |
| NCT05662410 | Kim´s Eye Hospital|Nune Eye Hospital, Seoul, Korea|HanGil Eye Hospital | Pachychoroid Neovasculopathy | 2022-12-26 | PHASE4 |
| NCT06205979 | Sohag University | Diabetic Macular Edema | 2023-12-12 | EARLY_PHASE1 |
| NCT03597815 | Uptown Eye Specialists | Diabetic Macular Edema|Sleep Apnea|Non Proliferative Diabetic Retinopathy | 2018-01-01 | |
| NCT01843725 | Jules Bordet Institute | Metastatic Colorectal Cancers|Metastatic Gastric Cancers|Metastatic Oesophageal Cancers|Metastatic Pancreatic Cancers|Metastatic Biliary Cancers|Metastatic Breast Cancers | 2013-09 | PHASE1 |
| NCT02296567 | East Florida Eye Institute|Genentech, Inc. | Age Related Macular Degeneration | 2014-12 | PHASE2|PHASE3 |
| NCT04793100 | Fondation Ophtalmologique Adolphe de Rothschild|Bayer | Central Retinal Vein Occlusion | 2021-03-24 | NA |
| NCT02381730 | Fondation Ophtalmologique Adolphe de Rothschild | Polypoidal Choroidal Vasculopathy | 2014-01 | NA |
| NCT04641234 | Bayer | Neovascular Age-related Macular Degeneration | 2020-12-11 | |
| NCT02645266 | McMaster University | Diabetic Macular Edema | 2018-05-01 | NA |
| NCT01722045 | Regeneron Pharmaceuticals | Age - Related Macular Degeneration (AMD) | 2012-11 | PHASE4 |
| NCT07423429 | Nantes University Hospital | Exudative Age-Related Macular Degeneration | 2026-02 | |
| NCT01724554 | Ophthalmic Consultants of Boston|Regeneron Pharmaceuticals | Central Retinal Vein Occlusion|Proliferative Diabetic Retinopathy | 2012-11 | PHASE1|PHASE2 |
| NCT01482910 | Bayer|Regeneron Pharmaceuticals | Macular Degeneration | 2011-12 | PHASE3 |
| NCT01688960 | Regeneron Pharmaceuticals|Sanofi | Solid Tumors | 2012-10 | PHASE1 |
| NCT02980874 | Clearside Biomedical, Inc. | Macular Edema|Retinal Vein Occlusion | 2017-01-31 | PHASE3 |
| NCT06942520 | Sierra Eye Associates|REGENXBIO Inc. | Diabetic Macular Edema | 2025-03-18 | PHASE2 |
| NCT00532155 | Sanofi|Regeneron Pharmaceuticals | Carcinoma|Non Small Cell Lung | 2007-09 | PHASE3 |
| NCT00396591 | Sanofi|Regeneron Pharmaceuticals | Ovarian Neoplasms | 2006-10 | PHASE2 |
| NCT03941587 | Singapore National Eye Centre|National University Hospital, Singapore|Tan Tock Seng Hospital | Polypoidal Choroidal Vasculopathy | 2021-02-01 | NA |
| NCT04527107 | Oxurion | Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema | 2020-07-31 | PHASE2 |
| NCT05110209 | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 2020-07-15 | |
| NCT01710332 | Wills Eye|Regeneron Pharmaceuticals | Central Serous Chorioretinopathy | 2012-10 | PHASE2 |
| NCT06146309 | Al-Azhar University | Branch Retinal Vein Occlusion | 2020-12-01 | NA |
| NCT00509795 | Regeneron Pharmaceuticals|Bayer | Macular Degeneration | 2007-08 | PHASE3 |
| NCT01543568 | David M. Brown, M.D.|Regeneron Pharmaceuticals | Age Related Macular Degeneration | 2012-02 | PHASE4 |
| NCT02274259 | Anders Kvanta | Central Retinal Vein Occlusion | 2014-10 | PHASE4 |
| NCT03767738 | Regeneron Pharmaceuticals | Chorioretinal Vascular Disease | 2018-12-19 | PHASE4 |
| NCT03297684 | Advanced Eye Research Associates | Diabetic Macular Edema | 2018-04-11 | |
| NCT03085784 | Amy C Schefler, MD|Regeneron Pharmaceuticals | Radiation Retinopathy | 2017-07-05 | PHASE2 |
| NCT04311606 | Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals | Thyroid Eye Disease | 2020-11-02 | PHASE2 |
| NCT06116916 | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 2024-01-09 | PHASE2 |
| NCT06422507 | Bayer|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2024-05-29 | PHASE3 |
| NCT04153253 | Al Hadi Hospital | Diabetic Vitreous Hemorrhage | 2018-03-07 | PHASE4 |
| NCT02976012 | Southeast Retina Center, Georgia | Proliferative Diabetic Retinopathy | 2016-06 | PHASE1|PHASE2 |
| NCT03382587 | Bayer|Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 2017-12-05 | |
| NCT02850263 | Bayer | Macular Edema | 2016-07-05 | |
| NCT04707625 | Wake Forest University Health Sciences | Retinal Vein Occlusion | 2021-10-06 | PHASE4 |
| NCT01148615 | Sanofi|Regeneron Pharmaceuticals | Neoplasm Malignant | 2010-07 | PHASE1 |
| NCT03397264 | Opthea Limited | Diabetic Macular Edema | 2018-01-16 | PHASE1|PHASE2 |
| NCT03279289 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Sanofi | Metastatic Colorectal Cancer | 2017-10-25 | PHASE2 |
| NCT01749956 | SCRI Development Innovations, LLC|Sanofi | Rectal Cancer | 2013-01 | PHASE2 |
| NCT07449923 | EyePoint Pharmaceuticals, Inc. | Diabetic Macular Edema|DME|Diabetic Macular Edema (DME) | 2026-02-09 | PHASE3 |
| NCT07389980 | Yeungnam University College of Medicine|Bayer | Polypoidal Choroidal Vasculopathy|Polypoidal Choroidal Vasculopathy (PCV) | 2026-12-24 | PHASE3 |
| NCT04919096 | Clover Biopharmaceuticals AUS Pty | Wet Age-related Macular Degeneration | 2022-04 | PHASE1 |
| NCT02384759 | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 2015-05 | PHASE2 |
| NCT03197480 | Singapore National Eye Centre|Santen Pharmaceutical Co., Ltd.|Singapore Eye Research Institute | Diabetic Macular Edema | 2019-04-17 | PHASE4 |
| NCT04740931 | Hoffmann-La Roche|Chugai Pharmaceutical | Macular Edema|Central Retinal Vein Occlusion|Hemiretinal Vein Occlusion | 2021-03-02 | PHASE3 |
| NCT07390253 | Vienna Institute for Research in Ocular Surgery | Neovascular (Wet) Age-Related Macular Degeneration | 2024-09-18 | |
| NCT04288232 | Taipei Veterans General Hospital, Taiwan|Kaohsiung Veterans General Hospital.|National Taiwan University Hospital|Chang Gung Memorial Hospital | Center-involved Diabetic Macular Edema | 2015-08-31 | PHASE3 |
| NCT06668064 | EyePoint Pharmaceuticals, Inc. | Wet Age Related Macular Degeneration|wAMD | 2024-10-22 | PHASE3 |
| NCT04047472 | Novartis Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 2019-11-29 | PHASE3 |
| NCT03953079 | Graybug Vision | Neovascular Age-Related Macular Degeneration | 2019-09-26 | PHASE2 |
| NCT07235527 | Saglik Bilimleri Universitesi | Age Related Macular Degeneration|Exudative Age-Related Macular Degeneration|Anti Vascular Endothelial Growth Factor | 2025-11-20 | |
| NCT01711879 | University of Colorado, Denver | Neovascular Glaucoma | 2013-01 | NA |
| NCT03043729 | AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi | Rectal Cancer|Rectosigmoid Cancer | 2017-03-06 | PHASE2 |
| NCT02081339 | Kyoto University, Graduate School of Medicine | Macular Disease | 2014-03 | |
| NCT07438119 | Kun Liu|The Second Affiliated Hospital of Harbin Medical University|Peking University People´s Hospital|The General Hospital of Central Theater Command|First Affiliated Hospital of Fujian Medical University|Zhongshan Ophthalmic Center, Sun Yat-sen University|Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University|The First Affiliated Hospital of Dalian Medical University|West China Hospital|The First People´s Hospital of Xuzhou | Diabetic Macular Edema (DME) | 2026-03-15 | PHASE4 |
| NCT05587062 | Cinnagen | Age-Related Macular Degeneration|Neovascular Age-related Macular Degeneration | 2019-10-01 | PHASE3 |
| NCT01657669 | Retina Research Institute, LLC|Valley Retina Institute | Age Related Macular Degeneration | 2012-10 | PHASE4 |
| NCT01714115 | Vitreous -Retina- Macula Consultants of New York|Regeneron Pharmaceuticals | Retinal Hemangioma | | |
| NCT00437034 | National Cancer Institute (NCI) | Stage II Multiple Myeloma|Stage III Multiple Myeloma | 2007-01 | PHASE2 |
| NCT02651168 | Unity Health Toronto | Diabetic Macular Edema | 2016-03 | PHASE4 |
| NCT02289924 | Bayer | Wet Macular Degeneration | 2015-01-09 | |
| NCT05885503 | RemeGen Co., Ltd. | Diabetic Macular Edema | 2023-06-08 | PHASE3 |
| NCT06662994 | Retina Consultants of Orange County|Regeneron Pharmaceuticals | Diabetic Macular Edema (DME) | 2025-07-07 | PHASE4 |
| NCT01882868 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2013-07 | PHASE2 |
| NCT02718326 | Regeneron Pharmaceuticals | Nonproliferative Diabetic Retinopathy | 2016-03-29 | PHASE3 |
| NCT05847049 | Dar El Oyoun Hospital | Central Serous Chorioretinopathy | 2023-02-28 | |
| NCT06929507 | University Hospital, Alexandroupolis | Renal Function Disorder|Diabetic Macular Edema (DME)|Neovascular Age Related Macular Degeneration | 2025-03-10 | NA |
| NCT01930552 | Sanofi|Regeneron Pharmaceuticals | Neoplasm Malignant | 2013-09 | PHASE1 |
| NCT03730558 | Recherche clinique | Metastatic Colon Cancer | 2017-11-08 | |
| NCT02573038 | Hospices Civils de Lyon | Choroidal Neovascularization in Angioid Streaks | 2016-02 | PHASE2 |
| NCT02457026 | Duke University|Bausch & Lomb Incorporated | Neovascular Age-related Macular Degeneration | 2016-01 | NA |
| NCT02434328 | Alcon Research | Neovascular Age-Related Macular Degeneration|Choroidal Neovascularization | 2015-07-28 | PHASE3 |
| NCT05146687 | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 2020-07-15 | |
| NCT03804099 | Augenabteilung Allgemeines Krankenhaus Linz | Macular Degeneration|Anti Vascular Endothelial Growth Factor | 2017-03-01 | PHASE4 |
| NCT02299336 | Greater Houston Retina Research|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2014-11-24 | PHASE4 |
| NCT06856577 | Adverum Biotechnologies, Inc. | Neovascular Age-Related Macular Degeneration (nAMD)|Wet AMD | 2025-02-28 | PHASE3 |
| NCT02257632 | Novartis Pharmaceuticals | Wet Age-Related Macular Degeneration | 2015-04-08 | PHASE4 |
| NCT01790893 | John Kitchens, MD | Ocular Histoplasmosis | 2013-03 | PHASE1|PHASE2 |
| NCT02633852 | Hadassah Medical Organization|Bayer | Diabetic Macular Edema (DME) | 2016-05-24 | PHASE4 |
| NCT06075147 | Bayer | Visual Impairment|Neovascular Age-related Macular Degeneration (nAMD)|Diabetic Macula Edema (DME) | 2024-02-15 | |
| NCT03313401 | Ulucanlar Eye Training and Research Hospital | Age Related Macular Degeneration | 2017-01 | |
| NCT06850571 | Al-Mustansiriyah University|Baghdad Medical City | Diabetic Maculopathy | 2025-02-20 | PHASE4 |
| NCT03797547 | Poitiers University Hospital | Myopic Choroidal Neovascularisation | 2018-06-22 | |
| NCT04101721 | Regeneron Pharmaceuticals | Retinopathy of Prematurity | 2019-10-30 | PHASE3 |
| NCT03845049 | Centre Hospitalier Universitaire Dijon | Macular Telangiectasia | 2019-07-03 | PHASE3 |
| NCT02204683 | University of Nebraska|Regeneron Pharmaceuticals | Neovascular Macular Degeneration | 2014-09-05 | PHASE1 |
| NCT03712670 | Università degli Studi di Brescia | Retinal Disease | 2016-01-01 | NA |
| NCT01909791 | Jaeb Center for Health Research|Regeneron Pharmaceuticals|National Eye Institute (NEI)|National Institutes of Health (NIH) | Diabetic Macular Edema | 2013-10 | PHASE3 |
| NCT01988246 | Rishi Singh|Regeneron Pharmaceuticals | Diabetic Retinopathy | 2013-12 | PHASE1|PHASE2 |
| NCT02040220 | Bayer|Regeneron Pharmaceuticals | Retinal Vein Occlusion | 2014-01-24 | |
| NCT00519285 | Sanofi|Regeneron Pharmaceuticals | Prostatic Neoplasms|Neoplasm Metastasis | 2007-08 | PHASE3 |
| NCT02712008 | Regeneron Pharmaceuticals|Bayer | Diabetic Macular Edema | 2016-03-02 | PHASE2 |
| NCT03396861 | Tufts Medical Center|Regeneron Pharmaceuticals | Irvine-Gass Syndrome | 2019-02-22 | PHASE1 |
| NCT05282420 | South Valley University | Non-Ischemic Central Retinal Vein Occlusion With Macular Edema | 2021-02-01 | PHASE4 |
| NCT00284141 | Sanofi|Regeneron Pharmaceuticals | Pulmonary Diseases|Neoplasms, Lung | 2006-01 | PHASE2 |
| NCT01661270 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2012-07 | PHASE3 |
| NCT07317934 | Innostellar Biotherapeutics Co.,Ltd | Neovascular Age-Related Macular Degeneration (nAMD)|Wet AMD | 2026-01-14 | PHASE3 |
| NCT06850922 | Genentech, Inc. | Diabetic Macular Edema | 2022-06-22 | PHASE1|PHASE2 |
| NCT02537054 | University Hospital, Bonn | Pseudoxanthoma Elasticum | 2015-09 | PHASE2 |
| NCT04810585 | Yonsei University | Recurrent or Metastatic Colorectal Cancer | 2020-04-20 | PHASE4 |
| NCT04252456 | Gruppo Italiano per lo studio dei Carcinomi dell´Apparato Digerente | Advanced Colorectal Cancer | 2018-04-23 | NA |
| NCT01661972 | John Strickler, M.D.|Sanofi | Metastatic Colorectal Cancer | 2012-08 | PHASE1|PHASE2 |
| NCT02045030 | CR-CSSS Champlain-Charles-Le Moyne|Sanofi|Regeneron Pharmaceuticals|Quebec Clinical Research Organization in Cancer | Metastatic Colorectal Cancer | 2014-01 | PHASE2 |
| NCT02669953 | Medical University of Vienna | Age Related Macular Degeneration|Intravitreal Injections|Diabetic Macular Edema | 2015-12 | |
| NCT06321302 | Boehringer Ingelheim | Diabetic Retinopathy | 2024-05-15 | PHASE2 |
| NCT01997164 | Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema | 2014-11 | PHASE1 |
| NCT05324592 | Mabwell (Shanghai) Bioscience Co., Ltd. | Diabetic Macular Edema | 2021-02-26 | PHASE1 |
| NCT04588948 | Stanford University|Regeneron Pharmaceuticals | Diabetic Macular Edema | 2020-12 | PHASE2 |
| NCT01578720 | Retina Research Institute, LLC | Choroidal Neovascularization|Presumed Ocular Histoplasmosis | 2012-06 | PHASE1 |
| NCT03577899 | Chengdu Kanghong Biotech Co., Ltd. | Neovascular Age-related Macular Degeneration | 2018-09-25 | PHASE3 |
| NCT02713204 | Regeneron Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 2016-03-31 | PHASE2 |
| NCT04331730 | Alkahest, Inc. | Neovascular Age-related Macular Degeneration | 2020-01-28 | PHASE2 |
| NCT02821247 | Bayer | Choroidal Neovascularization|Macular Degeneration | 2016-07-01 | |
| NCT02307682 | Alcon Research | Neovascular Age-Related Macular Degeneration|Choroidal Neovascularization | 2014-12-08 | PHASE3 |
| NCT06116890 | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 2024-01-31 | PHASE2 |
| NCT01802684 | GERCOR - Multidisciplinary Oncology Cooperative Group|Sanofi | Unresectable Metastatic Colorectal Cancer | 2013-05 | PHASE2 |
| NCT01783925 | Bayer|Regeneron Pharmaceuticals | Macular Degeneration | 2014-04-29 | |
| NCT01571284 | Sanofi|Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 2012-05-30 | PHASE3 |
| NCT05662943 | Kim´s Eye Hospital | Polypoidal Choroidal Vasculopathy|Choroidal Neovascularization|Age-Related Macular Degeneration | 2022-12-05 | |
| NCT06610747 | Zhongshan Ophthalmic Center, Sun Yat-sen University|Dongguan Guangming Ophthalmic Hospital|The Second People´s Hospital of Foshan | Diabetic Macular Edema | 2024-10-28 | NA |
| NCT07105228 | Regeneron Pharmaceuticals | Retinal Vasculitis | 2025-07-15 | |
| NCT02550002 | Insel Gruppe AG, University Hospital Bern | Age Related Macular Degeneration | 2015-12 | |
| NCT03481660 | Novartis Pharmaceuticals | Diabetic Macular Edema | 2018-07-27 | PHASE3 |
| NCT07340372 | Association for Innovation and Biomedical Research on Light and Image | Exudative Age-Related Macular Degeneration | 2026-05 | |
| NCT02174211 | King´s College Hospital NHS Trust|King´s College London | Age Related Macular Degeneration | 2014-06 | NA |
| NCT05769153 | Alcon Research | Neovascular Age-related Macular Degeneration (nAMD) | 2023-12-06 | PHASE1|PHASE2 |
| NCT02033018 | Instituto de Olhos de Goiania | Choroidal Retinal Neovascularization | 2013-10 | PHASE4 |
| NCT03802630 | Novartis Pharmaceuticals | Branch Retinal Vein Occlusion | 2019-07-02 | PHASE3 |
| NCT02634333 | Jaeb Center for Health Research|Regeneron Pharmaceuticals|Juvenile Diabetes Research Foundation|National Eye Institute (NEI)|National Institutes of Health (NIH) | Diabetic Retinopathy|Diabetic Macular Edema | 2016-01 | PHASE3 |
| NCT04075188 | Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | Choroidal Neovascularization|Choroid Disease | 2017-09-18 | NA |
| NCT02257502 | Hospices Civils de Lyon | Idiopathic Choroidal Neovascularization | 2015-07-06 | PHASE2 |
| NCT00320775 | Regeneron Pharmaceuticals|Bayer | Macular Degeneration | 2005-06 | PHASE1 |
| NCT00527423 | Regeneron Pharmaceuticals|Bayer | Macular Degeneration | 2007-08 | PHASE2 |
| NCT00601991 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Leukemia | 2007-03 | PHASE2 |
| NCT00357760 | National Cancer Institute (NCI) | Metastatic Renal Cell Carcinoma | 2007-12 | PHASE2 |
| NCT00383370 | Regeneron Pharmaceuticals | Neovascular Age Related Macular Degeneration | 2006-10 | PHASE1 |